Combi natorial peptide chemistry and phage display technologies have contributed to the pool of available peptide ligands as cancer imaging constructs. Lead peptides are identified on the basis of high affinity and target selectivity in vitro and applied to the imaging modality of choice for their evaluation in vivo. Radiolabeled peptides for PET imaging are of interest because of PET's high sensitivity and quantitative properties, and the small size of peptides inherently gives them relatively fast pharmacokinetic properties. Successful examples include arginine-glycine-aspartic acid peptide analogs, which have been investigated extensively for targeting a v b 3 integrin (1-3), and octreotide peptides against the somatostatin receptor 2 (4, 5) . However, the development of peptide ligands with the preferred attributes of high affinity, target selectivity, high stability, and desirable pharmacokinetic properties is challenging. Most peptide ligands developed do not possess these preferred attributes and are often deemed inadequate for imaging. Approaches to prolong the residence time of peptide ligands to their targets have been used to improve affinity, stability, and pharmacokinetic properties (2, 3, 6, 7) . Peptides can be modified to improve and extend the duration of target uptake by implementing covalent and permanent chemical attachment to the target, an approach that remains relatively unexplored.
Vascular endothelial growth factor (VEGF) is an important biomarker overexpressed in various cancers that stimulates endothelial cell proliferation and migration, leading to the formation of new blood vessels from preexisting ones (angiogenesis) (8) . Although a secreted protein, VEGF can bind noncovalently to the extracellular matrix in the tumor vasculature, a property that allows VEGF to be targeted similarly to cell membrane-bound tumor biomarkers (9) . VEGF has been successfully targeted for therapeutic and diagnostic applications, with the anti-VEGF monoclonal antibody, bevacizumab. Bevacizumab is approved by the Food and Drug Administration for antiangiogenesis treatment and has also been radiolabeled for noninvasive PET and SPECT imaging of VEGF (10) (11) (12) (13) (14) . Radiolabeled Affibody (Affibody AB) molecules have also been investigated as VEGF imaging probes because of their nanomolar affinity for VEGF and robust structure (11) .
The v107 peptide binds to VEGF with micromolar affinity, a characteristic that is generally considered as insufficiently potent for targeted molecular imaging (15, 16) . Enhancing peptide ligand binding to its target by converting this reversible interaction with VEGF to a covalent and irreversible reaction will eliminate the peptide's dissociation from VEGF and may potentially improve target uptake. Hence, v107 was redesigned by substituting its leucine-19 residue to lysine, resulting in L19K, and was conjugated to a small library of amine-reactive cross-linkers for site-specific covalent attachment to VEGF residue lysine-48 (17) . The natural affinity of the peptide for VEGF brings the peptide's cross-linker into close proximity to VEGF lysine-48 and facilitates a covalent bond formation. The lead peptide, L19K-(5-fluoro-2,4-dinitrobenzene) (L19K-FDNB), was most reactive with VEGF, compared with other L19K conjugates in vitro (17) . For the present studies, L19K-FDNB was modified to incorporate 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) at the peptide's N terminus (NO2A). We radiolabeled the peptide with 64 Cu ( 64 Cu half-life 5 12.7 h; b 1 5 17.8%, E max 5 653 keV; b 2 5 38.4%, E max 5 578 keV), because 64 Cu-NOTA complexes are stable in vitro and in vivo (18) (19) (20) . We hypothesized the radiolabeled irreversible peptide agent 64 Cu-L19K-FDNB would improve tumor uptake, compared with its reversibly binding peptide analogs 64 Cu-L19K-(2,4-dinitrophenyl) (64Cu-L19K-DNP) and 64 Cu-L19K. Herein, we evaluate the radiolabeled irreversible peptide agent that binds covalently to VEGF as a PET imaging probe in tumor-bearing mice.
MATERIALS AND METHODS

Reagents
Chemicals and organic solvents were purchased from SigmaAldrich unless stated otherwise. Milli-Q (18 MV; EMD Millipore) water was used for all buffer preparations. Cell culture reagents were purchased from Life Technologies. 64 CuCl 2 was produced in house according to previous methods (21 The purification and monitoring of reaction completion followed previous methods (17) . L19K-DNP was synthesized by conjugating L19K to 1-fluoro-2,4-dinitrobenzene (FDNP) as described above. The molecular weight was confirmed using electrospray ionization mass spectrometry. Peptide concentrations were estimated using a Nanodrop ultravioletvisible spectrophotometer (Thermo Scientific) at A 350 nm (e 5 17,000 cm 21 M 21 ) for L19K-FDNB and L19K-DNP (22) and at A 280 nm (e 5 11,500 cm 21 M 21 ) for unconjugated L19K at pH 6-7 (23).
Radiolabeling with 64 Cu 64 CuCl 2 was buffered in 0.1 M Et 3 N•HOAc, pH 6. L19K, L19K-DNP, and L19K-FDNB (5 mg) buffered with 0.1 M Et 3 N•HOAc, pH 6, was added to 18.5-37 MBq (0.5-1 mCi) of 64 CuCl 2 to a final concentration of 33 mM peptide, and 5 mL of 5 mM ascorbic acid were added as a radioprotectant in a total volume of 50 mL (24) . Radiolabeling was performed at 37°C for 20 min. High-performance liquid chromatography was performed to determine radiochemical purity.
Small-Animal PET/CT Imaging and Biodistribution
The institutional animal use committee approved all animal studies. Athymic Nu/Nu mice (National Cancer Institute; age, 6-9 wk) were anesthetized with a ketamine/xylazine cocktail (VEDCO) before subcutaneous injection with 150 mL of approximately 3 · 10 7 cells/mL of high-VEGF-expressing HCT-116 or low-VEGF-expressing SSTR2-SKOV3 suspended in saline. Tumors were allowed to grow 40-200 mm 3 for 1-2 wk.
HCT-116 tumor-bearing mice were injected with 100 mL of 7.4 MBq (200 mCi) of 64 Cu-L19K-FDNB, 64 Cu-L19K-DNP, or 64 Cu-L19K via the tail vein. Mice were sacrificed at 24 h (n 5 3-5), 48 h (n 5 3), and 72 h (n 5 3) after injection for biodistribution studies, and the 48-h subset of mice was imaged by PET/CT at 24 and 48 h after injection. Unlabeled L19K-FDNB (138 mg) was coinjected with 1.8 mg of 64 Cu-L19K-FDNB (7.4 MBq, n 5 3) in saline for a total volume of 200 mL for blocking studies at 48 h after injection. The preliminary pharmacokinetic studies of 64 Cu-L19K-FDNB were investigated in both HCT-116 and SSTR2-SKOV3 xenografts.
Details about additional methods are provided in the supplemental materials (available at http://jnm.snmjournals.org).
RESULTS
Peptide Characterization, Radiolabeling, and Stability
The conjugation of L19K to either DFDNB or FDNP linkers ( ½Fig: 1 Fig. 1 ) resulted in quantitative conversion of L19K to L19K-FDNB or L19K-DNP, respectively, characterized by mass spectrometry (Supplemental Figs. 1 and 2). Subsequent radiolabeling of L19K-FDNB, L19K-DNP, and the native L19K with 64 Cu each gave a 95% or more radiochemical yield, with retention times of 17.7, 17.6, and 13.1 min, respectively (Supplemental Figs. 3-5). The specific activity was 11.1 GBq/mmol. The radiolabeled peptides were used for in vitro and in vivo studies without further purification. In vitro serum stability studies of 64 Cu-L19K, 64 Cu-L19K-DNP, and 64 Cu-L19K-FDNB were performed in a 1:1 phosphate-buffered saline:fetal bovine serum solution (pH 7.4) at 37°C for up to 24 h. All peptides showed no 64 Cu decomplexation and minimal peptide degradation up to 24 h (Supplemental Figs. 6-8 ). Some nonspecific binding of 64 Cu-L19K-FDNB to serum proteins was observed at 24 h (Supplemental Fig. 8 ). Further stability studies with 64 Cu-L19K-FDNB spiked with excess unlabeled L19K-FDNB in phosphatebuffered saline (pH 7.4) to monitor the fluoroaromatic cross-linker at A 350 nm resulted in a relatively stable product with minimal hydrolysis at 24 h (Supplemental Fig. 9 ).
In Vitro Binding Studies 64 Cu-L19K-FDNB, 64 Cu-L19K-DNP, and 64 Cu-L19K were bound to 2-fold equivalents of soluble VEGF in a phosphate-buffered solution, and these reactions were subsequently analyzed via autoradiographic sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis under denaturing conditions in the absence (nonreducing) and presence of a thiol-containing reducing agent (reducing). Under nonreducing conditions, the total protein stain showed bands for noncovalently bound VEGF migrating between 25 and 37 kDa, whereas covalently bound VEGF migrated between 37 and 50 kDa ( ½Fig: 2 Fig. 2A ). Although total protein stain does not detect the peptides at the concentration used, the autoradiogram of the same gel confirms the migration pattern of each 64 Cu-labeled peptide (Fig. 2B) . Only 64 Cu-L19K-FDNB completely reacted covalently to VEGF, migrating between 37 and 50 kDa (Fig. 2B, lane 1) , and the corresponding total protein stain showed 2 bands of about equal intensity associated with unreacted VEGF migrating between 25 and 37 kDa and covalently reacted VEGF migrating between 37 and 50 kDa ( Fig. 2A,  lane 1 ). An attempt to reverse this nucleophilic aromatic substitution product with a b-mercaptoethanol-reducing agent did not displace 64 Cu-L19K-FDNB from the VEGF monomer, migrating between 20 and 25 kDa (Figs. 2C and 2D) . 64 Cu-L19K-DNP and 64 Cu-L19K did not bind covalently to VEGF, indicated by the absence of this band between 20 and 25 kDa and the presence of unreacted 64 Cu-L19K-DNP and 64 Cu-L19K at the bottom of the gel (Fig. 2, lanes 2 and 3) . Under reducing conditions, VEGF unlocks its disulfide bonds to release free sulfhydryl groups, which transchelated some 64 Cu in the control reaction (Fig. 2D, lane  4) ; however, this transchelation was not observed in the 64 Cu-NO2A-peptide reactions (Fig. 2D, lanes 1-3) . The reactivity of 64 Cu-L19K-FDNB was further examined with mouse VEGF, because our in vivo models express endogenous mouse VEGF. As expected, 64 Cu-L19K-FDNB also covalently bound to mouse VEGF because of the conserved epitope recognized by the peptide in both homologs (Supplemental Fig. 10) (16, 17, 25) .
Cellular binding studies were performed to investigate the specificity of 64 Cu-L19K-FDNB using VEGF-expressing HCT-116 cells. The cellular uptake of 17.8% 6 9.06% was observed with significant reduction to 1.75% 6 0.51% (P , 0.05) when pretreated with unlabeled L19K-FDNB and 0.56% 6 0.24% (P , 0.05) with bevacizumab ( ½Fig: 3 Fig. 3 ). Cellular uptake comparing the blocking conditions using unlabeled L19K-FDNB and bevacizumab were not significant (P . 0.05).
In Vivo Small-Animal PET Imaging and Biodistribution
We first evaluated the pharmacokinetic properties of 64 Cu-L19K-FDNB in tumor-bearing mice with varying levels of VEGF expression at 2, 24, and 48 h after injection. The expression of somatostatin receptor 2 (SSTR2) is reported to downregulate VEGF expression (26, 27) , thus a transfected cell line, SSTR2-SKOV3, was used as a low-level human VEGF model. The validation of SSTR2 transfection in the SSTR2-SKOV3 cells was performed via flow cytometry and shows positive expression of Fig. 11 ). Human VEGF expression levels in the 2 cell lines were determined via Western blotting, confirming higher VEGF expression with HCT-116 than SSTR2-SKOV3 (Supplemental Fig. 12 ). Biodistribution studies for 64 Cu-L19K-FDNB at 2 h after injection yielded similar tumor uptake (P . 0.05) between HCT-116 and SSTR2-SKOV3 xenografts, suggesting passive uptake. At 24 h, higher tumor-associated radioactivity was observed in HCT-116 than in SSTR2-SKOV3 tumor xenografts, with 3.36 6 0.33 (n 5 5) and 1.76 6 0.60 percentage injected dose per gram (%ID/g) (n 5 5, P , 0.01), respectively (Supplemental Fig. 13 ). This difference was also significant at 48 h (P , 0.01) (Supplemental Fig.  13 ). Blood clearance was similar in both xenograft models, in which blood residency decreased by 2-fold after each time point (Supplemental Fig. 13 ). High kidney uptake was initially observed in both models: 32.42 6 7.71 %ID/g at 2 h, decreasing to 5.65 6 0.69, and 3.83% 6 0.56% %ID/g at 24 and 48 h, respectively, in HCT-116 mice (Supplemental Fig. 13 ). The similar biodistribution of 64 Cu-L19K-FDNB in nontarget organs of both models is indicative of binding to endogenous mouse VEGF. These results suggest that optimal imaging can be achieved at later time points, for which higher tumor uptake in the high-VEGF-expressing tumor and a decrease in renal-and bloodstream-associated radioactivity were achieved. Thus, successive imaging studies were conducted starting from 24 h after injection.
SSTR2 (Supplemental
Blocking studies were performed to evaluate the in vivo specificity of 64 Cu-L19K-FDNB by coinjection with 138 mg of unlabeled L19K-FDNB. PET imaging studies showed a significant decrease in tracer tumor uptake in the presence of excess unlabeled L19K-FDNB ( ½Fig: 4 Fig. 4A ). Biodistribution studies corroborate PET imaging studies, in which a 53% reduction 64 Cu-L19K-FDNB tumor binding was observed, decreasing from 3.12 6 0.43 to 1.48 6 0.36 %ID/g (n 5 3, P 5 0.008) (Fig. 4B) . In addition to the tumor, liver and kidney uptake were also reduced in the presence of unlabeled L19K-FDNB. Liver uptake was reduced by 56% from 5.73 6 0.59 to 2.53 6 0.78 %ID/g (n 5 3, P 5 0.006), and kidney uptake was reduced by 63% from 3.83 6 0.56 to 1.41 6 0.23 %ID/g under nonblocking and blocking conditions, respectively (n 5 3, P 5 0.009) (Fig. 4C) . These results suggest that 64 Cu-L19K-FDNB is selective for VEGF, and blocking in normal organs may be attributed to endogenously expressed VEGF (28, 29) .
Comparison of 64 Cu-L19K-FDNB, 64 Cu-L19K-DNP, and 64 Cu-L19K
64 Cu-labeled L19K-FDNB, L19K-DNP, and L19K were evaluated by PET imaging at 24 and 48 h after injection and by biodistribution studies at 24, 48, and 72 h in HCT-116 xenografts. Quantitative region-of-interest analysis of PET images revealed that 64 Cu-L19K-FDNB has the highest tumor uptake, compared with the lipophilic 64 Cu-L19K-DNP and the native 64 Cu-L19K, with a mean standardized uptake value (SUV) of 0.62 6 0.05, 0.18 6 0.06, and 0.34 6 0.14, respectively, at 24 h after injection and 0.53 6 0.05, 0.32 6 0.14, and 0.30 6 0.09, respectively, at 48 h after injection ( ½Fig: 5 Fig. 5 ). Statistical analysis determined significant differences (P , 0.05) between 64 Cu-L19K-FDNB and each control peptide at both 24 and 48 h after injection. Differences between 64 Cu-L19K-DNP and the native 64 Cu-L19K were not significant at either time point (P . 0.05). Biodistribution values follow the same trend as SUV; however, the intertumoral variability and small sample size in these terminal studies does not provide statistical power to be significant at individual time points. At 24 h, the tumor uptake values were 3.94 6 0.98, 2.43 6 0.55, and 2.83 6 0.80 %ID/g for 64 Cu-L19K-FDNB, 64 Cu-L19K-DNP, and 64 Cu-L19K, respectively (Supplemental Table 1 ). At this time point, only the difference between 64 Cu-L19K-FDNB and 64 Cu-L19K-DNP was significant (P 5 0.004), but the difference between 64 Cu-L19K-FDNB and 64 Cu-L19K was not significant (P . 0.05). Also, the difference between 64 Cu-L19K-DNP and 64 Cu-L19K was not significant (P . 0.05). Furthermore, statistical analyses for the 48-and 72-h data did not yield significant differences among the peptides at each of these time points (Supplemental Tables 2 and 3 ). However, the collective effect of 64 Cu-L19K-FDNB at all time points (n 5 9) gave enough statistical power to be significantly different from 64 Cu-L19K-DNP (n 5 12, P 5 0.0092) and 64 Cu-L19K (n 5 9, P 5 0.025), whereas the difference between 64 Cu-L19K-DNP and 64 Cu-L19K was not significant (P . 0.999). Thus, the tumor uptake of the covalent binding 64 Cu-L19K-FDNB surpasses those of its noncovalent analogs, 64 Cu-L19K-DNP and 64 Cu-L19K.
DISCUSSION
We evaluated a radiolabeled irreversible peptide agent, 64 Cu-L19K-FDNB, as a PET imaging probe for VEGF in tumor-bearing mice. In diagnostic imaging, affinity-enhanced covalent binding of peptide probes has thus far been applied only to pretargeting methods involving the covalent binding of a radiolabeled peptide to an engineered targeting vector rather than directly to a natural biomarker (30) . Other affinity-enhanced covalent binding imaging agents based on small ligands have also been investigated in artificial receptors in vivo, yielding excellent imaging contrast because of the probe's fast pharmacokinetic properties and improved affinity for its target (31, 32) . Exploring this concept to target a natural biomarker using a peptide ligand is relatively uncharted. As proof of concept, we applied the previously developed L19K-FDNB ligand that binds covalently and irreversibly to VEGF as a PET imaging agent, to improve the potency of low-affinity peptide probes (14, 15) .
Substituting 64 Cu-NO2A as the detection moiety at the peptide's N terminus did not affect the cross-linking reaction of L19K-FDNB to VEGF. This strategy requires the noncovalent binding equilibrium between peptide and VEGF to bring the peptide's cross-linker into close proximity to VEGF Lys-48 to facilitate a nucleophilic aromatic substitution reaction, while remaining unreactive to other nucleophilic amino acid side chain groups ( ½Fig: 6 Fig. 6 ) (17) . Exemplified by in vivo pharmacokinetic studies, 64 Cu-L19K-FDNB is capable of differentiating varying VEGF expression levels between HCT-116 and SSTR2-SKOV3 tumor xenografts at 24 h (P , 0.01) and 48 h (P , 0.01) after injection. Additionally, background in normal tissues requires several hours to resolve so we focused on imaging at later times. Other factors such as different tumor vascularization or irregular tumor growth may also affect the biodistribution of 64 Cu-L19K-FDNB other than VEGF expression levels, and more studies are needed to analyze these physiologic differences. However, we have shown in vivo specificity for VEGF in our blocking studies, in which a 53% reduction in tumor-associated activity was observed in the presence of excess unlabeled peptide (P 5 0.008) in the HCT-116 xenografts (Fig. 4) . Other organs expressing endogenous VEGF such as the liver, kidneys, and blood were also significantly blocked (P , 0.05). This cross-reactivity of 64 Cu-L19K-FDNB to mouse VEGF, also verified in vitro (Supplemental Fig. 10) , predicts a more relevant biodistribution for clinical purposes.
Because the incorporation of the fluoroaromatic cross-linker changes the lipophilicity of the peptide, we compared 64 Cu-L19K-FDNB with a similar but unreactive peptide conjugate, 64 Cu-L19K-DNP, serving as a lipophilic peptide control. High-performance liquid chromatography analysis of 64 Cu-L19K-DNP shows a retention time similar to 64 Cu-L19K-FDNB at 17.6 and 17.7 min, respectively. In vitro binding studies show that 64 Cu-L19K-FDNB binds covalently and irreversibly to VEGF, whereas 64 Cu-L19K-DNP and the native 64 Cu-L19K do not bind covalently (Fig. 2) . Although it is difficult to prove covalent binding in vivo, results from in vitro binding studies and the structural similarity between the 64 Cu-L19K-FDNB and 64 Cu-L19K-DNP suggest that any differences between these probes in vivo are more likely due to covalent binding of 64 Cu-L19K-FDNB. Comparative studies between these peptide conjugates along with the native 64 Cu-L19K in vivo showed highest tumor uptake with 64 Cu-L19K-FDNB at 24 and 48 h after injection (P , 0.05), as determined by PET imaging using SUV analysis (Fig. 5) . Biodistribution studies support SUV analysis with the same trend at 24 and 48 h; however, a larger sample population size is necessary at the individual time points to achieve statistical power. These terminal studies contribute a larger intertumoral variability, especially when the sample size is small. PET imaging studies follow the same subset of mice at the different time points so that the variability between mice over time are reduced. Two-way ANOVA analysis determined the biodistribution studies at 24, 48, and 72 h after injection collectively confirm the tumor uptake of 64 Cu-L19K-FDNB is significantly higher than 64 Cu-L19K-DNP (P 5 0.009) or 64 Cu-L19K (P 5 0.025), the difference between 64 Cu-L19K-DNP and 64 Cu-L19K was not significant (P . 0.999). Thus, the lipophilicity contributed by the cross-linkers in 64 Cu-L19K-FDNB and 64 Cu-L19K-DNP does not appear to improve tumor uptake, and the improved tumor uptake is consistent with the covalent binding 64 Cu-L19K-FDNB. Overall, our results indicate that the enhancement of peptide ligand binding via irreversible binding is a promising tool to advance low-affinity peptides as molecular imaging agents and improve tumor accumulation.
CONCLUSION
64 Cu-L19K-FDNB enhances tumor uptake, compared with the noncovalent binding 64 Cu-L19K-DNP and 64 Cu-L19K, in vivo. Covalent binding peptides offer a means to improve the performance of low-affinity peptides in vivo and warrant further investigations in other peptide-target systems.
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